Fuquan Jiang
Research Subjects
Fuquan Jiang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Xinquan Gu
Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, China.
2 shared publications Bo Li
State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China
1 shared publicationFan Wang
State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China
1 shared publication- Jiansong Han
Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, China
1 shared publication - Jingjing Li
State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China
1 shared publication - Kai Liu
Engineering Research Center of Advanced Rare Earth Materials (Ministry of Education) Department of Chemistry Tsinghua University Beijing China
1 shared publication
Latest Publications
- 7 November 2025
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 258, 115265
Light-triggered nanozyme system amplifies oxidative stress for precision cancer therapy
- 7 November 2025
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 258, 115265
Light-triggered nanozyme system amplifies oxidative stress for precision cancer therapy
- Open Access
- 24 August 2022
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 7 (35) , 31299-31308
Long-Lasting Proteinaceous Nanoformulation for Tumor Imaging and Therapy
Nanodrugs have attracted increasing interest in drug delivery and disease treatment. However, the cumbersome preparation process and the poor biocompatibility of nanodrugs obstruct their clinical translation. In this study, we utilized a self-assembly strategy to develop a low-toxicity, long-lasting nanodrug for the effective treatment and real-time monitoring of bladder tumors. The accurate self-assembly of compatible raw materials allowed for an encapsulation rate of 43.7% for insoluble erdafitinib. Interestingly, robust therapeutic effects and reduced side effects could be realized simultaneously using this nanodrug, enabling broader scenarios for the clinical application of erdafitinib. Furthermore, the nanodrug exhibited a significantly prolonged in vivo half-life (14.4 h) and increased bioavailability (8.0 mu g/mL & BULL;h), which were 8.3 times and 5.0 times higher than those of its nonformulated counterpart. Also, it is worth mentioning that the introduction of a fluorescent protein module into the nanodrug brought up a novel possibility for real-time feedback on the therapeutic response. In conclusion, this research revealed a versatile technique for developing low-toxicity, long-acting, and multifunctional nanoformulations, paving the way for multidimensional therapy of malignant tumors.
- 24 August 2022
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 7 (35) , 31299-31308
Open AccessLong-Lasting Proteinaceous Nanoformulation for Tumor Imaging and Therapy
Nanodrugs have attracted increasing interest in drug delivery and disease treatment. However, the cumbersome preparation process and the poor biocompatibility of nanodrugs obstruct their clinical translation. In this study, we utilized a self-assembly strategy to develop a low-toxicity, long-lasting nanodrug for the effective treatment and real-time monitoring of bladder tumors. The accurate self-assembly of compatible raw materials allowed for an encapsulation rate of 43.7% for insoluble erdafitinib. Interestingly, robust therapeutic effects and reduced side effects could be realized simultaneously using this nanodrug, enabling broader scenarios for the clinical application of erdafitinib. Furthermore, the nanodrug exhibited a significantly prolonged in vivo half-life (14.4 h) and increased bioavailability (8.0 mu g/mL & BULL;h), which were 8.3 times and 5.0 times higher than those of its nonformulated counterpart. Also, it is worth mentioning that the introduction of a fluorescent protein module into the nanodrug brought up a novel possibility for real-time feedback on the therapeutic response. In conclusion, this research revealed a versatile technique for developing low-toxicity, long-acting, and multifunctional nanoformulations, paving the way for multidimensional therapy of malignant tumors.